College of Food Science and Engineering, Ocean University of China, No. 5 Yushan Road, Qingdao 266003, P. R. China.
Food Funct. 2019 Jul 17;10(7):3955-3964. doi: 10.1039/c9fo01147a.
Sea cucumber saponins (SCS) exhibit a significant effect on ameliorating glucose and lipid disorders by inhibiting fatty acid biosynthesis; however, high cytotoxicity and hemolytic activity limit their application. Eicosapentaenoic acid-enriched phospholipids (EPA-PL) significantly ameliorate insulin resistance and elevate the level of hepatic lipolysis, which may have a synergistic effect with SCS in alleviating obesity-related insulin resistance via multiple mechanisms. In the present study, high-fat diet-induced male C57BL/6J mice with obesity-related insulin resistance were used to evaluate the synergistic effect of SCS and EPA-PL on alleviating the insulin resistance. Results show that the combination of SCS and EPA-PL at a half dose exhibited a significant improvement on glucose intolerance and systematic insulin sensitivity than SCS or EPA-PL alone. Moreover, the half dose-combination remarkably inhibited the macrophage infiltration (F4/80) to white adipose tissue (WAT) and significantly down-regulated the level of MCP1, TNF-α and IL-6 compared with SCS and EPA-PL alone. Consequently, the combined administration not only decreased hepatic gluconeogenesis and increased hepatic glycogen synthesis (P < 0.05), but also stimulated the glucose uptake in WAT and muscle (P < 0.05). Nevertheless, neither SCS or EPA-PL alone exhibited any effect on the glucose uptake. The combination of SCS and EPA-PL contributed to a synergistic effect on alleviating the obesity-related insulin resistance due to the amelioration of an inflammation-centric peripheral insulin response.
海参皂苷(SCS)通过抑制脂肪酸合成,对改善葡萄糖和脂质代谢紊乱具有显著作用;然而,其高细胞毒性和溶血活性限制了其应用。富含二十碳五烯酸的磷脂(EPA-PL)显著改善胰岛素抵抗,提高肝脏脂肪分解水平,这可能通过多种机制与 SCS 协同缓解肥胖相关的胰岛素抵抗。在本研究中,使用高脂肪饮食诱导的肥胖相关胰岛素抵抗雄性 C57BL/6J 小鼠来评估 SCS 和 EPA-PL 联合缓解胰岛素抵抗的协同作用。结果表明,SCS 和 EPA-PL 的半剂量组合在改善葡萄糖耐量和系统胰岛素敏感性方面优于 SCS 或 EPA-PL 单独使用。此外,与 SCS 和 EPA-PL 单独使用相比,半剂量组合显著抑制了巨噬细胞向白色脂肪组织(WAT)的浸润(F4/80),并显著下调了 MCP1、TNF-α 和 IL-6 的水平。因此,联合给药不仅降低了肝糖异生,增加了肝糖原合成(P < 0.05),还刺激了 WAT 和肌肉中的葡萄糖摄取(P < 0.05)。然而,SCS 或 EPA-PL 单独使用均对葡萄糖摄取没有影响。SCS 和 EPA-PL 的联合使用有助于协同缓解肥胖相关的胰岛素抵抗,这是由于改善了以炎症为中心的外周胰岛素反应。